alexa The Inhibition Of Breast Cancer Cell Metastasis By Anti-ErbB2 Humanized Antibody ChA21 With A New Recognition Epitope | 15854
ISSN: 1948-5956

Journal of Cancer Science & Therapy
Open Access

Like us on:

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

3rd World Congress on Cancer Science & Therapy

Guodong Shen
ScientificTracks: J Cancer Sci Ther
DOI: 10.4172/1948-5956.S1.028
Abstract
It is well known that ErbB2 (HER2/p185her2/neu) overexpression in human malignant cancers correlates with poor prognosis and chemo-resistance. Monoclonal antibody drug trastuzumab (herceptin) is used in the treatment of clinical tumors with considerable success, but the insensitivity or resistant phenomenon in tumor therapy is increasingly serious. Our previous results demonstrate that our independently developed new humanized antibody chA21 has a different ErbB2 recognition epitope from those of trastuzumab and other antibody drugs, and also exerts a marked inhibition effect for ErbB2-positive breast cancer and ovarian cancer growth in vitro and in vivo . In this study, we found that chA21 might significantly inhibit ErbB2-overexpressing breast cancer cell migration and invasion by BT-474 and SKBR-3 cell adhesion, invasion and spreading assays, and in contrast, trastuzumab had no remarkable effects. Further, it was shown that chA21 might promote cell-cell attachment, decrease cell migration capacity and inhibit the interaction between cell and extracellular matrix (ECM), which was not mediated by E-cadherin protein, but presumably through promoting the internalization and degradation of ErbB2 and other family receptors by inducing the polymerization of receptor complexes. These results indicated that chA21 might not only inhibit ErbB2 downstream signal transduction, but also down-regulate signaling crosstalk with other receptors. In conclusion, our findings show that chA21 may represent a unique anti-ErbB2 antibody with potentials as therapeutic candidate alone or combination with other tumor-targeted drugs in cancer therapy.
Biography
Guodong Shen has studied cellular and molecular characteristics and immunotherapy of breast, ovarian and stomach tumors with ErbB2 overexpression more than six years, during which time he has authored more than 20 peer-reviewed papers. Currently, he is the director of Molecular Medicine Key Lab of Anhui Provincial Hospital, a premier organization for cancer immunotherapy in China. He is also serving as an editorial board member of a Chinese clinical medicine journal and a council member of Anhui Provincial Health Administration Society in China.
image PDF   |   image HTML
 

Relevant Topics

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2018-19
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri & Aquaculture Journals

Dr. Krish

[email protected]

+1-702-714-7001Extn: 9040

Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals

Ronald

[email protected]

1-702-714-7001Extn: 9042

Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001Extn: 9040

Clinical Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

Food & Nutrition Journals

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

General Science

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics & Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Materials Science Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Nursing & Health Care Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

Ann Jose

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001Extn: 9042

 
© 2008- 2018 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
Leave Your Message 24x7